Literature DB >> 26027477

Device-associated infection rates and bacterial resistance in six academic teaching hospitals of Iran: Findings from the International Nocosomial Infection Control Consortium (INICC).

Somayeh Jahani-Sherafat1, Maryam Razaghi1, Victor D Rosenthal2, Elahe Tajeddin1, Simasadat Seyedjavadi1, Marjan Rashidan1, Masoud Alebouyeh3, Maryam Rostampour4, Arezo Haghi5, Masoumeh Sayarbayat6, Somayeh Farazmandian7, Tahere Yarmohammadi8, Fardokht K Arshadi9, Nahid Mansouri10, Mohammad R Sarbazi11, Mariano Vilar2, Mohammad R Zali12.   

Abstract

Device-associated health care-acquired infections (DA-HAIs) pose a threat to patient safety, particularly in the intensive care unit (ICU). However, few data regarding DA-HAI rates and their associated bacterial resistance in ICUs from Iran are available. A DA-HAI surveillance study was conducted in six adult and pediatric ICUs in academic teaching hospitals in Tehran using CDC/NHSN definitions. We collected prospective data regarding device use, DA-HAI rates, and lengths of stay from 2584 patients, 16,796 bed-days from one adult ICU, and bacterial profiles and bacterial resistance from six ICUs. Among the DA-HAIs, there were 5.84 central line-associated bloodstream infections (CLABs) per 1000 central line-days, 7.88 ventilator-associated pneumonias (VAPs) per 1000 mechanical ventilator-days and 8.99 catheter-associated urinary tract infections (CAUTIs) per 1000 urinary catheter-days. The device utilization ratios were 0.44 for central lines, 0.42 for mechanical ventilators and 1.0 for urinary catheters. The device utilization ratios of mechanical ventilators and urinary catheters were higher than those reported in the ICUs of the INICC and the CDC's NHSN reports, but central line use was lower. The DA-HAI rates in this study were higher than the CDC's NHSN report. However, compared with the INICC report, the VAP rate in our study was lower, while the CLAB rate was similar and the CAUTI rate was higher. Nearly 83% of the samples showed a mixed-type infection. The most frequent pathogens were Acinetobacter baumannii, Staphylococcus aureus and Pseudomonas aeruginosa, followed by Klebsiella pneumoniae and Enterococcus spp. In the S. aureus isolates, 100% were resistant to oxacillin. Overall resistances of A. baumannii and K. pneumonia to imipenem were 70.5% and 76.7%, respectively. A multiple drug resistance phenotype was detected in 68.15% of the isolates. The DA-HAI rates in Iran were shown to be higher than the CDC-NHSN rates and similar to the INICC rates. Resistance to oxacillin and imipenem was higher as well. Comparing device use, DA-HAI rates, and bacterial resistance for the primary isolated bacteria indicated a direct association between urinary catheter use and the rates of CAUTI.
Copyright © 2015 King Saud Bin Abdulaziz University for Health Sciences. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bacterial resistance; Device-associated infection; Hospital infection; INICC; International Nosocomial Infection Consortium; Iran

Mesh:

Year:  2015        PMID: 26027477     DOI: 10.1016/j.jiph.2015.04.028

Source DB:  PubMed          Journal:  J Infect Public Health        ISSN: 1876-0341            Impact factor:   3.718


  13 in total

1.  [Antibiotic prophylaxis for short-term catheter bladder drainage in adults].

Authors:  S Schmidt; L Schneidewind
Journal:  Urologe A       Date:  2015-10       Impact factor: 0.639

2.  Visualizing Infection Surveillance Data for Policymaking Using Open Source Dashboarding.

Authors:  Monika Maya Wahi; Natasha Dukach
Journal:  Appl Clin Inform       Date:  2019-07-24       Impact factor: 2.342

3.  Device-Associated Healthcare-Associated Infections (DA-HAI) and the caveat of multiresistance in a multidisciplinary intensive care unit.

Authors:  Inam Danish Khan; Atoshi Basu; Sheshadri Kiran; Shaleen Trivedi; Priyanka Pandit; Anupam Chattoraj
Journal:  Med J Armed Forces India       Date:  2016-12-16

4.  Novel one-pot synthesis of a library of 2-aryloxy-1,4-naphthoquinone derivatives. Determination of antifungal and antibacterial activity.

Authors:  Katherine Chaves-Carballo; Guy V Lamoureux; Alice L Perez; Alexandre Bella Cruz; Valdir Cechinel Filho
Journal:  RSC Adv       Date:  2022-06-23       Impact factor: 4.036

5.  Morbidity, mortality, and emerging drug resistance in Device-associated infections (DAIs) in intensive care patients at a 1000-bedded tertiary care teaching hospital.

Authors:  Inam Danish Khan; Geetanjali Gonimadatala; S Narayanan; Umesh Kapoor; Harleen Kaur; Anuradha Makkar; R M Gupta
Journal:  Med J Armed Forces India       Date:  2021-10-28

6.  Assessment of extended-spectrum β-lactamases and integrons among Enterobacteriaceae in device-associated infections: multicenter study in north of Iran.

Authors:  Masoumeh Bagheri-Nesami; Alireza Rafiei; Gohar Eslami; Fatemeh Ahangarkani; Mohammad Sadegh Rezai; Attieh Nikkhah; Azin Hajalibeig
Journal:  Antimicrob Resist Infect Control       Date:  2016-12-01       Impact factor: 4.887

7.  Risk factors for hospital-acquired infections in teaching hospitals of Amhara regional state, Ethiopia: A matched-case control study.

Authors:  Walelegn Worku Yallew; Abera Kumie; Feleke Moges Yehuala
Journal:  PLoS One       Date:  2017-07-18       Impact factor: 3.240

8.  World-Wide Variation in Incidence of Staphylococcus aureus Associated Ventilator-Associated Pneumonia: A Meta-Regression.

Authors:  James C Hurley
Journal:  Microorganisms       Date:  2018-02-27

9.  Results after implementation of a protocol on the incidence of urinary tract infection in an intensive care unit.

Authors:  Anna Letícia Miranda; Ana Lúcia Lyrio de Oliveira; Daiana Terra Nacer; Cynthia Adalgisa Mesojedovas Aguiar
Journal:  Rev Lat Am Enfermagem       Date:  2016-09-09

10.  Evaluation of Risk Factors for Antibiotic Resistance in Patients with Nosocomial Infections Caused by Pseudomonas aeruginosa.

Authors:  Meliha Cagla Sonmezer; Gunay Ertem; Fatma Sebnem Erdinc; Esra Kaya Kilic; Necla Tulek; Ali Adiloglu; Cigdem Hatipoglu
Journal:  Can J Infect Dis Med Microbiol       Date:  2016-08-30       Impact factor: 2.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.